Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-resistance reactions in cancer cells

ABSTRACT: Molecular mechanisms and potential therapeutic drugs linking to cetuximab-resistance reactions in cancer cells

PROVIDER: PRJNA473145 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells

Project description:Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells

| PRJNA438483 | ENA

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HaCaT cells)

Project description:Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HaCaT cells)

| PRJNA438485 | ENA

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HEK 293 cells)

Project description:Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HEK 293 cells)

| PRJNA438486 | ENA

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-resistance reactions in cancer cells

Project description:To obtain differentially expressed genes associated with cetuximab resistance mechanism, we analyzed RNA samples using whole genome microarray expression profiling as a discovery platform to identify genes. Two kinds of RNA samples were extracted from SAS, Sa3, and HSC-3 cells: control cells and cetuximab-resistant cells.

2018-12-01 | GSE114928 | GEO

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HaCaT cells)

Project description:To obtain differentially expressed genes associated with cetuximab induced cytotoxicity we analyzed RNA samples using whole genome microarray expression profiling as a discovery platform to identify genes . Two kinds of RNA samples were extracted from HaCaT and HEK 293 cell; without cetuximab and incubation for 24 hours with 1.63μM (fixed maintenance dose) cetuximab.

2018-09-30 | GSE111885 | GEO

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HEK 293 cells)

2018-09-30 | GSE111886 | GEO

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-09-30 | GSE111887 | GEO

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Project description:HCC827 cells were grown in gradually increasing concentrations of cetuximab beginning at 0.1 ug/ml. Drug concentrations were slowly increased until the resistant cells were able to proliferate in 100 ug/ml of cetuximab. Individual clones of cetuximab resistant (CR; CR1 to CR4) cells were isolated and confirmed to be drug resistant. Number of samples: 5. Parental HCC827 as a control. 4 Cetuximab resistant clones

2011-11-23 | E-GEOD-30255 | biostudies-arrayexpress

Understanding molecular mechanisms of Cetuximab insensitivity in Colorectal Cancer (CRC)

Project description:Mutational status of KRAS in CRC is used to aid patient stratification for Cetuximab treatment. However, only a subset (10-40%) of patients with wt KRAS respond. We analyzed 40 mCRC tumors for Cetuximab response using a functional ex vivo platform. In the subset of non-responsive tumors, mutational (KRAS/BRAF and PIK3CA) and expression (AREG/EREG) analysis of key genes, transcriptomic profiling and GSEA were carried out to elucidate the molecular mechanisms underlying the response. Our analysis revealed deregulation of multiple pathways, notably Notch and Erbb2 and combined blockade of these two nodes elicited significant antitumor response. These findings collectively indicate the dependence of Cetuximab insensitive mCRC tumors on Notch and Erbb2 for survival and progression. 8 Primary tumors tested in ex vivo platform for response to Cetuximab were subjected to expression analysis

2014-04-01 | E-GEOD-56386 | biostudies-arrayexpress

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

2011-11-23 | GSE30255 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data